Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trialTamiru Shibiru Degaga, Geremew Gashaw Gessa, Bipin Adhikari et al.|The Lancet Infectious Diseases|2026Cited by 8
Effectiveness and Safety of High Dose Primaquine and Tafenoquine in Plasmodium vivax Patients (EFFORT) - A Multi-Centre, Open Label, Superiority Randomised Controlled TrialTamiru Shibiru Degaga, Ayodhia Pitaloka Pasaribu, Rupam Tripura et al.|SSRN Electronic Journal|2025Cited by 4
Risk of Recurrent Plasmodium vivax Malaria after Chloroquine Plus Low-Dose Primaquine in Pakistan: A Prospective Cohort StudyKamala Thriemer, M Beg, Najia Ghanchi et al.|SSRN Electronic Journal|2026Cited by 0